BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Bioshin rakes in $60M in series A funding led by Orbimed
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Bioshin rakes in $60M in series A funding led by Orbimed
Oct. 6, 2020
By
Gina Lee
No Comments
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.
BioWorld Asia
Financings
Neurology/psychiatric
Series A
Asia-Pacific